182 related articles for article (PubMed ID: 36630591)
1. The regulation of N6-methyladenosine modification in PD-L1-induced anti-tumor immunity.
Yu W; Lin J; Yu T; Lou J; Qian C; Xu A; Liu B; Tao H; Jin L
Immunol Cell Biol; 2023 Mar; 101(3):204-215. PubMed ID: 36630591
[TBL] [Abstract][Full Text] [Related]
2. N6-methyladenosine RNA modification in PD-1/PD-L1: Novel implications for immunotherapy.
Luo P; Li S; Long X
Biochim Biophys Acta Rev Cancer; 2023 May; 1878(3):188873. PubMed ID: 36842764
[TBL] [Abstract][Full Text] [Related]
3. The role of m6A-mediated PD-1/PD-L1 in antitumor immunity.
Liu L; Liang L; Li H; Shao W; Yang C; Lin F; Liu J; Zhang J
Biochem Pharmacol; 2023 Apr; 210():115460. PubMed ID: 36822438
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
5. The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors.
Tong H; Wei H; Smith AO; Huang J
Front Immunol; 2021; 12():802049. PubMed ID: 35069586
[TBL] [Abstract][Full Text] [Related]
6. JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA.
Ni Z; Sun P; Zheng J; Wu M; Yang C; Cheng M; Yin M; Cui C; Wang G; Yuan L; Gao Q; Li Y
Cancer Res; 2022 May; 82(9):1789-1802. PubMed ID: 35502544
[TBL] [Abstract][Full Text] [Related]
7. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
[TBL] [Abstract][Full Text] [Related]
8. m
Wang A; Sun Y; Wang X; Yan Z; Wang D; Zeng L; Lu Q
Aging (Albany NY); 2023 Aug; 15(16):8444-8457. PubMed ID: 37647025
[TBL] [Abstract][Full Text] [Related]
9. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
Liu X; Ma C; Liu H; Sun Z; Luo J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
[TBL] [Abstract][Full Text] [Related]
10. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
11. RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells.
Tsuruta N; Tsuchihashi K; Ohmura H; Yamaguchi K; Ito M; Ariyama H; Kusaba H; Akashi K; Baba E
Biochem Biophys Res Commun; 2020 Sep; 530(1):235-239. PubMed ID: 32828292
[TBL] [Abstract][Full Text] [Related]
12. Roles and therapeutic implications of m6A modification in cancer immunotherapy.
Pan J; Huang T; Deng Z; Zou C
Front Immunol; 2023; 14():1132601. PubMed ID: 36960074
[TBL] [Abstract][Full Text] [Related]
13. [Research Progress of m6A Methylation Modification in Hematological Tumors--Review].
Li F; Yang FF; Xu YL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1607-1611. PubMed ID: 36208274
[TBL] [Abstract][Full Text] [Related]
14. Integrated Analysis of the Immune Infiltrates and PD-L1 Expression of N6-Methyladenosine-Related Long Non-Coding RNAs in Colorectal Cancer.
Jiang Z; Zhang Y; Chen K; Yang X; Liu J
Int J Gen Med; 2021; 14():5017-5028. PubMed ID: 34511985
[TBL] [Abstract][Full Text] [Related]
15. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.
Meijing Z; Tianhang L; Biao Y
Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200
[No Abstract] [Full Text] [Related]
16. Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer.
Ji H; Zhang JA; Liu H; Li K; Wang ZW; Zhu X
Front Immunol; 2022; 13():976107. PubMed ID: 36091006
[TBL] [Abstract][Full Text] [Related]
17. Decreased Expression of Programmed Death Ligand-L1 by Seven in Absentia Homolog 2 in Cholangiocarcinoma Enhances T-Cell-Mediated Antitumor Activity.
Zheng H; Zheng WJ; Wang ZG; Tao YP; Huang ZP; Yang L; Ouyang L; Duan ZQ; Zhang YN; Chen BN; Xiang DM; Jin G; Fang L; Zhou F; Liang B
Front Immunol; 2022; 13():845193. PubMed ID: 35154166
[TBL] [Abstract][Full Text] [Related]
18. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
Jiang H; Ning G; Wang Y; Lv W
Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
[TBL] [Abstract][Full Text] [Related]
19. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Huang X; Qiu Z; Li L; Chen B; Huang P
Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma.
Nanamori H; Sawada Y
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]